Targeting polo-like kinase 1 in acute myeloid leukemia.

摘要: Polo-like kinase 1 (Plk1) plays a number of important roles in the passage cells through mitosis. It is expressed at high levels variety malignancies, including acute myeloid leukemia (AML). Inhibition Plk1 results cell cycle arrest and apoptosis, has anti-tumor effects pre-clinical models. A inhibitors have been developed, some which entered clinical trials. Of these, volasertib (BI6727) most extensively studied clinically AML. Volasertib demonstrated antileukemic activity AML, both as single agent when combined with low-dose cytarabine. well tolerated, major toxicity being reversible myelosuppression. recently completed phase III trial older AML patients will address question whether adding this to cytarabine associated survival advantage.